drugset / Trial / NCT00143806

Transitioning From Cyclosporine to Alefacept in Psoriasis

NCT00143806

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.

Timeline

Start
2003-10
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic
Subject Cyclosporine Peptide

Indications